Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region.

VEGF (vascular endothelial growth factor) regulates neovascularization through binding to its receptor KDR (kinase insert domain-containing receptor; VEGF receptor-2). We recently identified a catalytically inactive PLA(2) (phospholipase A(2)) homologue (KDR-bp) in the venom of eastern cottonmouth (Agkistrodon piscivorus piscivorus) as a third KDR-binding protein, in addition to VEGF(165) and tissue inhibitor of metalloproteinase-3. KDR-bp binds to the extracellular domain of KDR with a K(d) of 10(-8) M, resulting in specific blockade of endothelial cell growth induced by VEGF(165). Inactive PLA(2) homologues are widely distributed in the venoms of Viperidae snakes and are known to act as myotoxins. In the present study, we demonstrated that KDR-binding ability is a common characteristic for inactive PLA(2) homologues in snake venom, but not for active PLA(2)s such as neurotoxic and platelet aggregation-modulating PLA(2)s. To understand better the KDR and KDR-bp interaction, we resolved the binding region of KDR-bp using eight synthetic peptides designed based on the structure of KDR-bp. A synthetic peptide based on the structure of the C-terminal loop region of KDR-bp showed high affinity for KDR, but other peptides did not, suggesting that the C-terminal loop region of KDR-bp is involved in the interaction with KDR. The results of the present study provide insight into the binding of inactive PLA(2) homologues to KDR, and may also assist in the design of novel anti-KDR molecules for anti-angiogenic therapy.

[1]  V. Alakhov,et al.  A Vascular Endothelial Growth Factor High Affinity Receptor 1-specific Peptide with Antiangiogenic Activity Identified Using a Phage Display Peptide Library* , 2003, Journal of Biological Chemistry.

[2]  Ulrich Kuch,et al.  Biochemical and biological activities of the venom of the Chinese pitviper Zhaoermia mangshanensis, with the complete amino acid sequence and phylogenetic analysis of a novel Arg49 phospholipase A2 myotoxin. , 2006, Toxicon : official journal of the International Society on Toxinology.

[3]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[4]  A. Bikfalvi,et al.  Structure and Inhibitory Effects on Angiogenesis and Tumor Development of a New Vascular Endothelial Growth Inhibitor* , 2003, Journal of Biological Chemistry.

[5]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[6]  M. Ohno,et al.  Molecular evolution of myotoxic phospholipases A2 from snake venom. , 2003, Toxicon : official journal of the International Society on Toxinology.

[7]  B. Bahnson Structure, function and interfacial allosterism in phospholipase A2: insight from the anion-assisted dimer. , 2005, Archives of biochemistry and biophysics.

[8]  Takashi Morita,et al.  Identification of Vascular Endothelial Growth Factor Receptor-binding Protein in the Venom of Eastern Cottonmouth , 2005, Journal of Biological Chemistry.

[9]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[10]  T. Veikkola,et al.  Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Morita,et al.  Snake Venom Vascular Endothelial Growth Factors (VEGFs) Exhibit Potent Activity through Their Specific Recognition of KDR (VEGF Receptor 2)* , 2003, Journal of Biological Chemistry.

[12]  S. Soker,et al.  Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165 * , 1997, The Journal of Biological Chemistry.

[13]  Li Xiaoying,et al.  A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor* , 2002, The Journal of Biological Chemistry.

[14]  J. Drenth,et al.  A comparison of the crystal structures of phospholipase A2 from bovine pancreas and Crotalus atrox venom. , 1985, The Journal of biological chemistry.

[15]  S. Soker,et al.  Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. , 2001, Biochemical and biophysical research communications.

[16]  L. Claesson‐Welsh,et al.  A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 , 2003, Nature Medicine.

[17]  M. Shibuya,et al.  A Novel Snake Venom Vascular Endothelial Growth Factor (VEGF) Predominantly Induces Vascular Permeability through Preferential Signaling via VEGF Receptor-1* , 2004, Journal of Biological Chemistry.

[18]  B. Lomonte,et al.  An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. , 2003, Toxicon : official journal of the International Society on Toxinology.

[19]  M. Ohno,et al.  Discovery of novel [Arg49]phospholipase A2 isozymes from Protobothrops elegans venom and regional evolution of Crotalinae snake venom phospholipase A2 isozymes in the southwestern islands of Japan and Taiwan. , 2006, Toxicon : official journal of the International Society on Toxinology.

[20]  M. Hattori,et al.  Accelerated evolution in the protein-coding regions is universal in crotalinae snake venom gland phospholipase A2 isozyme genes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Morita,et al.  Identification of the heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165. , 2005, Biochemistry.

[22]  Wan-yu Wang,et al.  N49 phospholipase A2, a unique subgroup of snake venom group II phospholipase A2. , 2006, Biochimica et biophysica acta.

[23]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[24]  R. Kini Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. , 2003, Toxicon : official journal of the International Society on Toxinology.

[25]  T. Imamura,et al.  Augmentation of vascular permeability of VEGF is enhanced by KDR-binding proteins. , 2007, Biochemical and biophysical research communications.

[26]  E. Dennis,et al.  The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. , 2000, Biochimica et biophysica acta.

[27]  I. Križaj,et al.  The primary structure of ammodytin L, a myotoxic phospholipase A2 homologue from Vipera ammodytes venom. , 1991, European journal of biochemistry.

[28]  M. Ohno,et al.  Myotoxicity and physiological effects of three Trimeresurus flavoviridis phospholipases A2. , 1992, Biochemistry international.

[29]  Takashi Morita,et al.  Molecular and functional diversity of vascular endothelial growth factors , 2006, Molecular Diversity.

[30]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[31]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.